Veeda Clinical Research acquires Heads, a European CRO
March 30, 2024
Source: drugdu
94
Veeda Clinical Research has acquired Heads, a privately held European CRO, which specialises in conducting clinical trials in oncology. Established in 2010, Heads has operational presence in 25 multiple strategically important locations across Europe, North America and Asia Pacific region. Veeda expands its reach to major geographies and adds capabilities of late-sta. ge clinical trial execution with strong focus on oncology with this acqusition
The acquisition provides Heads a strong operational platform and an opportunity to expand its expertise and capabilities to the Indian and South-East Asian markets.
With this acquisition, Veeda’s global pharma and biotech clients can now avail early to late-phase CRO services across Europe, US, and Asia Pacific.
During the integration phase, Heads will continue to offer uninterrupted support to client programs.
https://www.vspharma.in/veeda-clinical-research-acquires-heads-a-european-cro/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Chuangxiang Biotechnology and Ikena Oncology merge to raise $75 million in funding December 25, 2024
- Two biosimilars of pembrolizumab have been approved for marketing, and the second indication of Cononospikinumab has been approved December 25, 2024
- ABB’s maintenance plan based on equipment status helps Jiheng Pharmaceutical December 25, 2024
- CR Group’s Big Move – Integration of Two Major Pharmaceutical Companies Completed December 25, 2024
- CanSino Biologics Launches Phase I/II Clinical Trials for Recombinant Polio Vaccine December 25, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
